MindMed

📍 New York, United States🗓 Founded 2019👥 88 employees💰 Last funded 2021
Biotechnology Research🌐 mindmed.co
Website LinkedIn
MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems. MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
6
Total investors
6
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

6 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
United States
4
Malta
1
United Kingdom
1
Investor activity2008–2021 · investors recorded per year
20081201932020120211
Recent (last 2y)Earlier
Frequently asked questions
Who invested in MindMed?
MindMed has 6 investors on record on gritt.io, including 6 early-stage backers.
When did MindMed last raise funding?
The most recent investment in MindMed recorded on gritt.io was in 2021.
When was MindMed founded?
MindMed was founded in 2019.
What industry is MindMed in?
MindMed operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is MindMed based?
MindMed is headquartered in New York, United States.